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We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108
tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet
endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial
ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer. The effect of prognostic variables on progression-free
and overall survival was assessed. On multivariate analysis, bulky residual disease after surgery was the best prognostic indicator
(Po0.001) for progression-free and overall survival (Po0.001). Lymphatic count was statistically significant as a prognostic factor
for progression-free (P¼0.05) and overall survival (P¼0.04). However, lymphatic count did not impact on survival curves. No
correlation was found between lymphatic count and age, histological subtype, FIGO stage or residual disease. Vascular count, VEGF
or TP expressions were not significant in either analysis. Lymphatic spread may be significant in aiding metastases in ovarian cancer but
requires other biological factors to act in conjunction, as it does not have clearcut prognostic significance. Dissemination of ovarian
cancer does not occur primarily through vascular or lymphatic routes but may occur through direct intraperitoneal spread of disease.
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Epithelial ovarian cancer has an annual incidence of 5000
women in the United Kingdom and is the most important cause
of gynaecological cancer-related mortality in the Western world.
Owing to the paucity of symptoms and their insidious onset, most
women present with advanced disease and 5-year survival rates
are approximately 30% (Agarwal and Kaye, 2003). Management
of ovarian cancer in most patients involves surgery to achieve
surgical cytoreduction followed by chemotherapy as surgical cyto-
reduction highly correlates with better patient survival (Cannistra,
2004). Residual disease of more than 2cm has traditionally
been associated with worse outcome. Sixty to seventy per cent of
patients initially respond to platinum-based chemotherapy and
approximately 40–50% achieve a complete clinical remission.
However, even in this latter group at least half of the patients
experience a recurrence within 4 years. Treatment following
relapse after initial chemotherapy is palliative in intent.
It has long been known that some cancers metastasise through
lymphatics to the regional lymphnodes before widespread
dissemination. This progression from locally confined disease to
lymph node spread confers a worse prognosis for the patient.
Lymphangiogenesis, that is, the formation of new lymphatic
vessels may play a role in this (Skobe et al, 2001; Stacker et al,
2001; Beasley et al, 2002). Animal models suggest that lymphan-
giogenesis occurs in malignancy and that inhibiting this process
can halt the spread to lymphatics (Makinen et al, 2001; Mandriota
et al, 2001; Shimizu et al, 2004). However, tumour cell invasion
of pre-existing lymphatics at the tumour margin can also occur
(Jackson et al, 2001; Pepper, 2001). Proliferation of lymph vessels
is regulated by members of the vascular endothelial growth factor
(VEGF) family and their receptors (Oh et al, 1997; Shimizu et al,
2004). VEGF-C and VEGF-D have been identified as stimulators of
lymphatic endothelial proliferation acting on VEGF receptor-3,
which functions as a specific receptor in adult tissues (Kaipainen
et al, 1995). Overexpression of VEGF C and VEGF D in ortho-
topically transplanted breast carcinoma cells in mice or in VEGF C
transgenic mice has been shown to promote tumour lymphangio-
genesis and subsequent lymph node metastasis (Pepper, 2001;
Skobe et al, 2001; Stacker et al, 2001).
Understanding the role of lymphatics in human cancers has
been improved by the recent identification of a number of novel
lymphatic receptors – lymphatic vessel endothelial hyaluronan
receptor (LYVE-1), Prox 1, podoplanin, b-chemokine receptor D6,
macrophage mannose receptor, desmoplakin that can discriminate
lymphatic vessels from blood vessels (Knudson and Knudson,
1993; Breiteneder-Geleff et al, 1999; Wigle et al, 2002; Scavelli et al,
2004). LYVE-1, one of the best studied lymphatic markers is a
lymph specific receptor for Hyaluronan (HA) (Banerji et al, 1999)
an abundant extracellular matrix glycosylaminoglycan which
Received 31 October 2005; revised 3 April 2006; accepted 5 April 2006;
published online 9 May 2006
*Correspondence: Professor TS Ganesan,
E-mail: tsganesan@aims.amrita.edu
The authors confirm this work to be original and that no parts of this
work have been previously published.
6Current address: Cancer Institute and Institute of Molecular Medicine,
Amrita Institute of Medical Sciences, Elamakkara P.O. Kochi, Kerala, India,
682026, E-mail: tsganesan@aims.amrita.edu
British Journal of Cancer (2006) 94, 1650–1657
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sfacilitates cell migration in wound healing, tumour metastasis
and inflammation by forming a pericellular matrix surrounding
fibroblasts and epithelial cells, reducing the level of intercellular
adhesion (Knudson and Knudson, 1993; Knudson et al, 1993).
LYVE-1 sequesters HA on lymph vessel endothelium, colocalises
with HA on the luminal surface of lymphatic vessels and
binds both soluble and immobilised HA exclusively (Prevo et al,
2001). LYVE-1 staining of lymphatics is demonstrated in virtually
every tissue where these structures could be distinguished and
includes vessels draining gastrointestinal tract, skin, lymph
nodes, breast and salivary gland and is distinct from blood vessel
staining (Banerji et al, 1999). However, LYVE-1 is also expressed in
normal liver blood sinusoids in mice and humans (Mouta Carreira
et al, 2001).
There is substantial crosstalk between angiogenesis and
lymphangiogenesis in tumour progression as evidenced by the
involvement of lymphangiogenic factors VEGF-C, D and their
receptor VEGFR3 in angiogenesis and the role played by
angiogenic factors VEGF-A and Angiopoetin 2 in lymphangiogen-
esis respectively (Scavelli et al, 2004). Vascular endothelial growth
factor is an endothelial cell-specific growth factor and the principal
regulator of angiogenesis under normal and pathological condi-
tions in most organs (Ferrara and Alitalo, 1999). Bevacizumab, a
VEGF-neutralising antibody has been shown to improve survival
in advanced colorectal cancer (Kabbinavar et al, 2005). Thymidine
phosphorylase (TP) is often induced in the tumour microenviron-
ment by physiological and chemical stress where it protects cells
from apoptosis and helps cell survival by stimulating nucleoside
metabolism and angiogenesis (Toi et al, 2005). The degree of
angiogenesis of a tumour as measured by vascular density has
emerged as a powerful candidate for prognosis and as a predictive
tool in breast cancer and melanomas (Bamberger and Perrett,
2002; Uzzan et al, 2004).
This study investigates the significance of tumour lymphatic
count and vascular count as well as angiogenic factors VEGF and
TP in epithelial ovarian malignancy as prognostic variables to
understand the pathogenesis of metastasis in ovarian cancer.
MATERIALS AND METHODS
Patient data
The clinical data for this study was collected from unselected
patients diagnosed with epithelial ovarian carcinoma between
1990 and 1998 who underwent surgery and treatment at the
Oxford Radcliffe Hospitals NHS trust (Oxford, UK). Patients with
a histological diagnosis of ovarian carcinoma (borderline tumours
were excluded) where follow-up data were known and with suffi-
cient tissue blocks for immunohistochemistry were included. The
patients were initially evaluated by clinical, ultrasound examina-
tion, computed axial tomography and serum tumour markers. All
patients were staged according to FIGO classification (Interna-
tional Federation of Gynaecology and Obstetrics).
Treatment consisted of surgery followed by chemotherapy
except in selected patients with Stage 1 disease. Patients who
underwent either bilateral salpingoophorectomy with total abdom-
inal hysterectomy and omentectomy or bilateral salpingoopho-
rectomy (where a hysterectomy had been performed previously)
were classified as having radical surgery whereas the rest were
classified as having debulking surgery to reduce tumour bulk.
Residual disease left in situ despite surgery was classified as either
microscopic, small volume residual disease o2cm or bulky
residual disease 42cm and information was obtained from the
operation summary. The majority of patients who received
chemotherapy had platinum-based regimens as first-line treat-
ment. Clinical response data for patients who received chemo-
therapy was assessed as follows – complete remission was defined
as the disappearance of all parameters of the disease; partial
remission was defined as a 50% reduction in the size of tumour
mass as defined radiologically and progressive disease was defined
as a 25% increase of any tumour mass or the development of a new
lesion. Overall and progression-free survival were classified as
outcome measures. Overall survival was defined as the period from
diagnosis until the time of death from any cause or, in patients
who were alive, until 1 June 2004. Progression-free survival was
calculated as the time period between diagnosis and relapse of
disease. Follow-up data were compiled until 1 June 2004.
Blocks from 93 patients were analysed for determination of
lymphatic count and 88 patients for vascular count and angiogenic
growth factors with some overlap between the two sets, that is, 74
patients had all parameters assessed. Clinicopathological data are
presented from a total of 108 patients. Funding organisations
approved but did not influence the conduct of the study. Formal
consent was obtained to conduct the study from the hospital
research and ethics committee.
Immunohistochemistry
Representative blocks of ovarian cancer with no normal tissue and
no large necrotic areas were selected. Three micrometre sections of
formalin-fixed, paraffin-embedded tissue were cut onto glass slides
and dried. Sections were dewaxed in xylene, rehydrated through
alcohol baths and rinsed in water.
Staining for lymphatic vessel endothelial hyaluronan
receptor
For LYVE-1 staining, slides were then pressure cooked for 2min at
full pressure in 0.1 M citrate buffer (pH 6.0) and rinsed in tap water.
The primary antibody (rabbit polyclonal anti-human LYVE-1)
was incubated for 60min at a 1/400 dilution, followed by 60min
incubation with the envision polymer (Banerji et al, 1999).
The slides were then stained on a Dako Techmate500t using
Dako EnVisiont Detection kit Peroxidase/DAB, rabbit/mouse
(Dako UK Ltd, Cambridgeshire, UK CB74E1 cat # K5007). Paraffin
sections of normal human small intestine were used as a positive
control; slides incubated without primary antibody were used
as a negative control.
Immunostaining for platelet endothelial cell adhesion
molecule
The JC70 monoclonal antibody, recognizing the pan-endothelial
antigen (platelet cell adhesion molecule, PECAM-1) was used as
described previously (Horak et al, 1992). Epitope retrieval was
performed by heat section in microwave for 30min in tris-
ethylenediaminetetraacetate (EDTA) buffer, and blocked in normal
human serum for 30minutes. Slides were incubated with primary
antibody JC70 (Dako, mouse monoclonal, Anti-Human CD31,
1:50) for 1h at room temperature. Horse anti-Mouse IgG at 1:100
for 30min at room temperature was used as secondary antibody
and the slides were developed using diluted horseradish per-
oxidase (HRP)–Streptavidin. A tissue section of breast carcinoma
previously known to demonstrate strong staining was used as
positive control; slides incubated without primary antibody were
used as a negative control.
Immunostaining for vascular endothelial growth factor
and thymidine phosphorylase
Antigen retrieval was performed using pressure-cooking for 3min
in Tris-EDTA (pH 9) for VEGF, endogenous peroxidase was then
quenched with Dako peroxidase block solution for 5min. The
primary antibody (murine monoclonal antibody VG76e/d9) was
applied, rinsed in phosphate-buffered saline and then developed
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(Turley et al, 1998). Sections were counterstained with haemato-
xylin and mounted.
For TP immunostaining, no antigen retrieval was performed and
was as described previously (Fox et al, 1995). The primary
antibody (mouse monoclonal antibody PGF 44-C) was applied as
undiluted supernatant for 30min at room temperature. After
washing in tris-buffered saline, sections were treated with rabbit
anti-mouse antibody (Dako) diluted 1 in 50 for 30min and
then mouse APAAP complex, 1 in 1, for 30min. The colour was
developed after 15min incubation with new fuschsin solution.
For VEGF, a section of breast carcinoma previously known to
demonstrate strong staining was used as a positive control, for TP
tumour-associated macrophages were used as an internal positive
control, slides incubated without primary antibody were used as a
negative control.
Quantitative analysis of lymphatic vessel, blood vessel
density and angiogenic growth factors
Only vessels with typical irregular morphology and a lumen that
stained with LYVE-1 antibody were considered lymphatic vessels
as some background staining of macrophages and tumour was
noted in some sections. The analysis of lymphatic vessel density
(LVD) was not restricted to vessels of any specific diameter as per
previous papers (Beasley et al, 2002; Williams et al, 2003). For the
microvessel count, small clusters of endothelial cells, with or
without a lumen, were considered as individual vessels; single-
stained endothelial cells were excluded. Microvessel density
(MVD) and LVD were determined in tumour vessel ‘hotspots’.
The slides were scanned at low magnification (at  10 and  40
for lymphatic vessel and microvessel count respectively) and areas
of highest lymphatic vessel or MVD were identified as ‘hotspots’.
Each hotspot was then viewed at high magnification using
a 0.25mm
2 microscope ocular grid (at  100 and  400 for
lymphatic and microvessel, respectively) and the number of vessels
counted in five high-power fields per hotspot. This approach has
been validated in published literature (Fox and Harris, 2004). The
mean of the vessels in three hotspots per slide was recorded.
Highest vessel density was also measured. As advanced ovarian
cancer penetrates the ovarian capsule, for the purposes of this
study no difference was made between intratumoral and peritu-
moral lymphatics (Vermeulen et al, 2002).
Staining for vascular endothelial growth factor was seen in
epithelial, macrophage, stromal and vascular tissue and for TP in
epithelial and stromal tissue. Expression was assessed by grading
each section on staining intensity with subjective scores ranging
from 0 to 3, 0 – negative, 1 – weak, 2– moderate and 3 – strong
expression as per previous published studies (Van der Auwera et al,
2004). For VEGF, a cumulative score from the four sites of staining
was calculated and stratified for analysis (0–3, 4–7, 8–12). The
counts were assessed by an operator without prior knowledge of
patient data and verified by an independent observer. The two
investigators agreed the count on most of the cases. Cases in
disagreement were jointly reviewed under a multiheaded microscope
and the consensus count was used for analyses.
Statistics
The Cox proportional hazards model in the Stata statistical
program was used to evaluate the putative prognostic indicators
considered (age, stage, residual disease, histological type, grade,
LVD and vascular density) and to assess any impact on the
outcome measures overall and progression-free survival (Cox and
Oakes, 1984). Univariate analysis is presented for all these factors.
Factors that were statistically significant on univariate analysis
were entered into a model to evaluate the prognostic impact on
outcome. For multivariate analysis, individual models with either
stage or residual disease were computed as both these variables are
closely linked, that is, patients with advanced stage disease are
more likely to have bulky residual disease after surgery. We also
present survival curves using the method of Kaplan and Meier
(Kaplan and Meier, 1958).
RESULTS
Patients
Clinicopathological data are presented for 108 patients (Table 1).
The median overall and progression-free survival was 28.44 and 21
months, respectively. Follow-up information was obtained from
Table 1 Clinicopathological characteristics of the patients
Characteristic All patients
Total no. 108
Age 25–88
Median age (years) 63
Histological type
Serous 35
Endometrioid 34
Clear cell 16
Mucinous 12
MMMT
a 4
Mixed epithelial 1
Undifferentiated 1
Primary peritoneal 3
Transitional cell carcinoma 1
Not known 1
Differentiation
Poor 29
Moderate–poor 7
Moderate 49
Well 20
Not known 3
FIGO Stage
I3 2
II 13
III 49
IV 14
Surgery
Radical 59
Debulking 46
Not known 3
Residual disease
Microscopic 53
p2cm 26
42cm 25
Not known 4
Chemo-response
Complete response 55
Partial response 10
Progressive disease 14
Early death 13
Not evaluable 8
Not known 8
Chemotherapy
Platinum 61
Non-platinum 14
No treatment 33
FIGO¼International Federation of Gynaecology and Obstetrics.
aDenotes malignant
mixed Mullerian tumour.
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a range of 0.49–165.29 months. A representative mix of histologies
and differentiation was noted in our data set. There was a roughly
equal distribution of early (Stage I and II) and advanced stage
(Stage III and IV) cancers, which is representative of practice at
Oxford. After initial surgery, 49% had microscopic disease, 24%
had residual disease p2cm and 23% had residual disease 42cm.
Fifty-six per cent of patients received platinum-based chemo-
therapy, 14% received nonplatinum-based chemotherapy and 30%
did not receive chemotherapy. Twenty-three of the 108 patients
were alive at the time of analysis.
Evaluation of staining
All but one tumour specimen stained with LYVE-1 antibody. All
tumours stained with antibody to CD31 but VEGF and TP staining
was more variable (see Supplementary data Table 1 online).
Immunostaining with the antibody to the LYVE-1 HA receptor
identified irregularly shaped, thin walled lymphatics in the
capsular and intratumoural regions of the tumour with capsular
lymphatics being more frequent than intratumoural lymphatics.
The lymphatics in a section of normal ovary (Figure 1A and B) and
tumour stained LYVE-1 antibody (Figure 1C–E). These were
distinguished from adjacent blood vessels, which were surrounded
by smooth muscle and were regular in shape. Median lymphatic
count was 18 (range 0–57). Roughly 52% of tumours had
lymphatic counts below the median, high lymphatic counts
(430) were noted in 16% of serous, 21% of endometroid, 7% of
clear cell and 20% of mucinous tumours.
Immunostaining with CD31 identified microvessels (Figure 1F).
Median vascular was 18.44 (range 7.6–39.75). A total of 61% of
tumours had vascular density counts below the median, high
Figure 1 Immunostaining of normal ovary and epithelial ovarian cancer with antibodies. Perifollicular lymphatics in normal ovary at  10 and  20
magnification (A and B). Lymphatic vessels adjacent to tumour at  10,  20 and  40 (C–E). Blood vessels containing RBC are not stained with LYVE-1
(marked with red arrow). Blood vessels in tumour at  20 (F). Vascular endothelial growth factor staining of tumour epithelium at  20 (VEGF) (G).
Epithelial staining of tumour (TP) at  20 (H). Arrowheads identify vessels and T marks tumour.
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svascular counts (430) were noted in 0% of serous, 7% of
endometroid, 7% clear cell and 27% mucinous tumours (Supple-
mentary data Table 1).
Vascular endothelial growth factor staining was noted in various
sites (stromal, macrophage, epithelial and vascular) and were
quantified (Figure 1G) whereas TP staining (Figure 1H) was noted
in the stroma and epithelium of the ovary. Strong staining of VEGF
was noted in 29% (epithelial), 17% (stromal), 43% (macrophage)
and 19% (vascular) of tumours. Strong staining with TP was noted
in 1% (epithelial) and 31% (stromal) of tumours (Supplementary
data Table 1).
Statistical analysis
In univariate analysis (Table 2), age (Po0.001), residual disease
(Po0.001) and FIGO stage (Po0.001) were associated with a
significantly shorter overall survival and progression-free survival.
In this set of patients, histological type or grade of differentiation
did not show impact on progression-free or overall survival.
Neither lymphatic nor vascular counts were statistically significant
on univariate analysis. An analysis of VEGF staining in various
sites and TP did not reveal any significance in univariate analysis.
On multivariate analysis (Table 3) two different mathematical
models – one with residual disease and the other with stage were
used to determine whether lymphatic density was an independent
Table 2 Univariate analysis on the association of the variables with the
outcome measures
Progression-free survival Overall survival
Variable HR 95% CI P-value HR 95% CI P-value
Age 1.03 1.01–1.05 0.01 1.03 1.01–1.05 0.001
Residual disease
Microscopic Baseline Baseline
p2cm 2.50 1.42–4.40 0.001 2.06 1.20–3.54 0.01
X2cm 7.07 3.94–12.67 o0.001 7.94 4.48–14.08o0.001
Stage
I Baseline Baseline
II 2.14 0.92–4.95 0.08 2.27 1.03–5.04 0.04
III 3.98 2.16–7.34 o0.001 3.78 2.12–6.74 o0.001
IV 6.69 2.82–15.86 o0.001 5.33 2.33–12.15o0.001
Histology
Baseline Baseline
Endometrioid
Clear cell 0.63 0.31–1.34 0.24 0.65 0.31–1.34 0.24
Mucinous 0.71 0.31–1.65 0.43 0.62 0.28–1.50 0.31
Serous 0.88 0.51–1.53 0.65 1.13 0.68–1.89 0.63
Others 1.25 0.54–2.89 0.60 1.35 0.59–3.11 0.48
Differentiation
Well Baseline Baseline
Moderate 1.42 0.73–2.73 0.30 1.32 0.72–2.43 0.37
Moderate–poor 0.77 0.62–5.04 0.29 1.80 0.69–4.69 0.23
Poor 1.92 0.95–3.87 0.07 1.59 0.81–3.12 0.17
Lymphatic count 1.01 0.99–1.03 0.30 1.01 0.99–1.03 0.41
Vascular count 0.99 0.95–1.02 0.53 0.98 0.95–1.02 0.34
TP
Stroma 1.00 0.81–1.24 0.96 1.11 0.90–1.38 0.33
0/1 vs 2 vs 3 1.01 0.76–1.35 0.94 1.14 0.85–1.51 0.38
0/1/2 vs 3 1.24 0.73–2.08 0.43 1.44 0.86–2.40 0.17
0/1 vs 2/3 0.86 0.53–1.41 0.56 1.06 0.65–1.74 0.81
Epithelium 1.21 0.73–2.04 0.46 1.07 0.63–1.80 0.80
VEGF
Epithelial 0.97 0.79–1.81 0.74 0.97 0.80–1.19 0.79
Macrophage 1.01 0.84–1.23 0.89 1.02 0.85–1.24 0.81
Stromal 1.01 0.80–1.28 0.94 0.99 0.78–1.26 0.94
Vascular 0.98 0.80–1.20 0.83 0.97 0.79–1.19 0.80
VEGF(0–3,4–7,8–12) 1.05 0.73–1.51 0.79 1.07 0.75–1.54 0.71
CI¼confidence intervals; HR¼hazards ratios; TP¼thymidine phosphorylase;
VEGF¼vascular endothelial growth factor. Age was analyzed as a continuous
variable. Univariate analysis of TP and VEGF expression was performed by
considering the trend in expression.
Table 3 Multivariate analysis on the association of the variables with
outcome measures. 3A Lymphatic count, 3B Vascular count, VEGF and TP
as variables
Progression-free survival Overall survival
Variable HR 95% CI P-value HR 95% CI P-value
(A)
Model I
Age 1.02 1.01–1.05 0.07 1.03 1.01–1.05 0.01
Lymphatic count 1.02 1.00–1.05 0.05 1.02 1.00–1.04 0.04
Residual disease
Microscopic Baseline Baseline
p2cm 2.21 1.16–4.20 0.02 1.64 0.088–3.06 0.12
X2cm 7.38 3.77–14.46 o0.001 7.43 3.86–14.31 o0.001
Model II
Age 1.02 1.00–1.05 0.05 1.03 1.00–1.05 0.02
Lymphatic count 1.01 0.99–1.03 0.27 1.01 0.99–1.03 0.19
Stage
I Baseline Baseline
II 1.57 0.63–3.94 0.34 1.62 0.68–3.84 0.27
III 3.31 1.74–6.31 o0.001 3.05 1.66–5.60 o0.001
IV 6.26 2.63–14.90 o0.001 4.21 1.88–9.68 o0.001
(B)
Model I
Age 1.02 0.99–1.04 0.11 1.03 1.01–1.05 0.04
Residual disease
Microscopic Baseline Baseline
p2cm 1.93 1.104– 3.58 0.04 1.79 0.97–3.22 0.06
X2cm 6.77 3.58–12.81 o0.001 7.63 4.00–14.58 o0.001
Vascular count 0.82 0.48–1.40 0.46 0.77 0.44–1.34 0.35
VEGFe 1.02 0.83–1.25 0.85 1.03 0.84–1.28 0.75
VEGFm 0.99 0.82–1.20 0.93 0.98 0.81–1.19 0.85
VEGFs 1.10 0.86–1.41 0.45 1.07 0.83–1.38 0.59
VEGFv 1.14 0.92–1.42 0.24 1.13 0.91–1.41 0.26
TPs 0.97 0.79–1.20 0.81 1.07 0.86–1.32 0.55
TPe 1.36 0.79–2.33 0.27 1.09 0.63–1.88 0.76
Model II
Age 1.01 0.99–1.04 0.34 1.02 0.99–1.04 0.16
Stage
I Baseline Baseline
II 2.07 0.85–5.00 0.11 2.25 0.95–5.32 0.07
III 3.41 1.77–6.59 o0.001 3.11 1.61–6.04 0.001
IV 4.44 1.63–12.10 o0.001 4.79 1.74–13.18 0.002
Vascular count 0.97 0.57–1.65 0.90 0.95 0.56–1.62 0.85
VEGFe 1.04 0.94–1.29 0.73 1.05 0.84–1.30 0.68
VEGFm 1.01 0.83–1.23 0.90 1.00 0.82–1.22 1.00
VEGFs 1.11 0.87–1.41 0.40 1.06 0.83–1.35 1.00
VEGFv 1.11 0.89–1.39 0.33 1.11 0.89–1.38 0.37
TPs 1.02 0.82–1.26 0.89 1.12 0.90–1.40 0.29
TPe 1.28 0.74–2.19 0.38 0.99 0.57–1.70 0.96
CI¼confidence intervals; HR¼hazards ratios; TP¼thymidine phosphorylase;
VEGF¼vascular endothelial growth factor.T
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sprognostic factor as residual disease and stage are closely related.
When all of the significant prognostic factors were taken into
account simultaneously in a Cox proportional hazards model, the
amount of residual disease was the strongest independent
prognostic indicator for overall survival and progression-free
survival (Po0.001). An analysis of this data set using the Cox
proportional hazards model comprising residual disease revealed
that lymphatic density reached statistical significance in progres-
sion-free survival (P¼0.05, hazards ratio (HR)1.00–1.05) and
overall survival (P¼0.04, HR 1.00–1.04). When this analysis
was repeated with another mathematical model comprising
stage and age, LVD was not shown to be of statistical significance.
Multivariate analysis using a model with residual disease indicated
that the vascular count was not associated with either overall
or progression-free survival. Mann–Whitney test did not reveal
any statistical significance for either LVD (P¼0.10) or MVD
(P¼0.87) for response to treatment. Similarly, expression levels
of VEGF and TP were not statistically significant in either
overall survival or progression-free survival using either of the
two models.
A Kaplan–Meier curve of survival (Figure 2) using a median
value of 18 lymphatic vessels as a cutoff did not show any
discrimination in survival with high- or low-lymphatic counts. In
addition, lymphatic count did not show any correlation with
residual disease (Krusker–Wallis P¼0.53, analysis of variance
P¼0.44) or with histology, differentiation of tumour or vascular
count. Lymphatic count did not predict any difference in survival
curves for the whole series or in a subset of Stage I patients.
DISCUSSION
The recent identification of immunohistochemical markers that
can reliably distinguish lymphatic vessels from blood vessels in
tissue sections has yielded new insight into the mechanisms of
metastasis. We investigated LVD, vascular density and angiogenic
factors in epithelial ovarian cancer in order to understand the
relative contributions of lymphatic and vascular spread in ovarian
cancer. This is the first report of LVD in ovarian cancer as
measured by LYVE-1, one of the best-characterised markers for
lymph vessels.
Our study found that on univariate analysis, both progression-free
and overall survival decreased significantly with age, in patients with
FIGO stage greater than II and in patients with residual disease after
surgery. This is consistent with published literature and clinical
practice. In multivariate analysis, using a model adjusting for age
and residual disease, LVD was statistically significant in progression-
free and overall survival. This was not replicated in another model
comprising age and stage of disease. A previous study in epithelial
ovarian cancer using a polyclonal antibody to podoplanin (Birner
et al, 2000) showed that intratumoural LVD was not a statistically
significant variable in overall or progression-free survival. This study
differed from the previous study in the following ways. We used
LYVE-1 as a lymphatic marker. It has been shown previously that
these antibodies/markers delineate identical lymphatic vessels on
tissue sections (Straume and Akslen, 2004). Secondly, we counted
three hotspots as opposed to one hotspot, which may give a more
representative view of the number of lymphatic vessels in the
tumour. We did not discriminate between intra- and peri-tumoral
vessels as ovarian cancer frequently penetrates the ovarian capsule
and assessment of LVD as a whole may be relevant in ovarian cancer.
Lymphovascular invasion in tissue sections of tumours has been
clearly documented to be a reliable prognostic variable predicting
nodal metastasis and survival in breast, cervix cancer and impacts
on decision making for therapy in testicular cancer (Warde
et al, 1997; Morice et al, 2003; Schoppmann et al, 2004; Dinshaw
et al, 2005). However, the prognostic significance of LVD in
cancer is not clearcut. In head and neck cancer, studies show an
association of increased LVD and new vessel formation with lymph
node metastasis and worse prognosis (Beasley et al, 2002; Maula
et al, 2003). In melanoma, one large study with 202 samples
demonstrated improved overall and recurrence free survival with
increased LVD in both peritumoural and intratumoural areas
(Straume et al, 2003) suggesting that vessel density may be a
marker for an improved immune response whereas two smaller
studies conclude the opposite with intratumoural lymphatics
significantly higher in metastatic melanomas and correlating with
poor survival (Dadras et al, 2003; Shields et al, 2004). Interestingly,
in breast cancer intratumoral lymphatic vessels are absent and the
significance of peritumoural vessels is unclear (Williams et al,
2003; Bono et al, 2004; Vleugel et al, 2004). Further studies in other
tumour types investigating LVD and proliferation markers may
clarify the role of new lymph vessel formation and the significance
of LVD in cancer progression.
Published studies with blood vessel density in ovarian cancers
are equivocal with some studies revealing an association with poor
prognosis whereas others dispute this (Hollingsworth et al, 1995;
Orre et al, 1998; Alvarez et al, 1999; Abulafia et al, 2000; Nakayama
et al, 2001). We found that MVD in an overlapping set of tumours
did not influence prognosis or survival or response to treat-
ment. Both VEGF and TP are important angiogenic factors for
many malignancies and have been postulated to work synergisti-
cally (Moghaddam et al, 1995; Ferrara, 2004). An analysis of the
expression of these angiogenic factors in our set of tumours
did not reveal any impact on survival. This is similar to
some published studies but is in contrast to others (Moghaddam
et al, 1995; Nishida et al, 2004; Raspollini et al, 2004; Sonmezer
et al, 2004).
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Figure 2 Kaplan–Meier survival plots of lymphatic vessel density in
ovarian cancer as an outcome measure for progression-free (A) and overall
survival (B). Lymphatic vessel counts are denoted as o or 418 as
indicated. Number of patients¼93.
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sLymphatic vessel density in our series was statistically significant in
multivariate analysis in overall survival and progression-free survival.
Lymphatic counts did not however, discriminate in survival curves.
This would suggest that lymphatic spread does not have absolute
prognostic significance but may act in conjunction with other biological
factors to aid metastasis in ovarian cancer. A larger study of Stage I
ovarian cancers will be useful in establishing the prognostic value of
LVD and whether this can be used to predict the need for chemo-
therapy in these patients. Ovarian cancer is primarily an abdominal
disease and our study would support the view that intraperitoneal
spread of ovarian cancer occurs through direct dissemination of disease
rather than through lymphatic or vascular spread.
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